Publications
PEER REVIEWED ORIGINAL CONTRIBUTIONS
Tagawa ST, Lee P, Snively J, Boswell W, Ounparseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for stage IV melanoma. Cancer 98: 144-154, 2003.
Israel V*, Tagawa ST*, Snyder T, Jeffers S, Raghavan D. Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer. Investigational New Drugs 2004; 22: 291-297.
Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in stage IV melanoma. Cancer 2006; 106: 1353-7.
Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn DI, Liebman HA. Subclinical hemostatic activation and surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int 2008 Jul 29; 102(9): 1086-91
INVITED CONTRIBUTIONS
Tagawa ST. Thrombosis in cancer: A review of epidemiology, plasma markers of hemostatic activation, fibrinolysis, and angiogenesis, and the potential use of heparins. Recent Res Devel Cancer 2004; 6(2): 295-310.
Arnason J, Tagawa ST, Bander NH. New and newer vascular targets in oncology. Commentary on Molecular Targets on Blood Vessels for Cancer Therapies in Clinical Trials. Oncology 2007; 21: 1376-80.
Tagawa ST. Commentary on: Phase II trial of paclitaxel, carboplatin, and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol 2008; Oct 16 [E pub ahead of print]
BOOKS AND CHAPTERS IN BOOKS
Tagawa ST, Hamid O, Skinner E, Kumar P. Uncommon Cancers of the Prostate. In Textbook of Uncommon Cancers, 3rd Ed. Raghavan D et al. Eds. Wiley & Sons, Ltd, 2006.
